Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0QM9Y
|
|||
Former ID |
DNC007340
|
|||
Drug Name |
KKHT-20918
|
|||
Synonyms |
KKHT-20918; CHEMBL224246; SCHEMBL8227894; IWAHUQRZIUVMSG-UHFFFAOYSA-N; KUC112514N; BDBM50196475; KSC-323-47-1-1; 3-(4-chlorobenzyl)-2,4-dioxo-N-(3-(piperidin-1-yl)propyl)-1,2,3,4-tetrahydroquinazoline-7-carboxamide; 3-(4-Chloro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid (3-piperidine-1-yl-propyl)-amide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C24H27ClN4O3
|
|||
Canonical SMILES |
C1CCN(CC1)CCCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
|
|||
InChI |
1S/C24H27ClN4O3/c25-19-8-5-17(6-9-19)16-29-23(31)20-10-7-18(15-21(20)27-24(29)32)22(30)26-11-4-14-28-12-2-1-3-13-28/h5-10,15H,1-4,11-14,16H2,(H,26,30)(H,27,32)
|
|||
InChIKey |
IWAHUQRZIUVMSG-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) | Target Info | Inhibitor | [1] |
KEGG Pathway | MAPK signaling pathway | |||
Calcium signaling pathway | ||||
Circadian entrainment | ||||
Type II diabetes mellitus | ||||
Panther Pathway | Endogenous cannabinoid signaling | |||
GABA-B receptor II signaling | ||||
Nicotine pharmacodynamics pathway | ||||
Pathwhiz Pathway | Muscle/Heart Contraction | |||
Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | |||
Reactome | NCAM1 interactions | |||
WikiPathways | NCAM signaling for neurite out-growth | |||
Nicotine Activity on Chromaffin Cells |
References | Top | |||
---|---|---|---|---|
REF 1 | Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.